The FDA’s Commissioner’s National Priority Voucher (CNPV) Pilot Program, launched in June 2025, creates a highly accelerated 1–2 month review pathway for products addressing key national health priorities such as unmet medical needs, domestic manufacturing resiliency, public health threats, healthcare affordability, and advanced therapeutic innovation. Entry into the program may occur through FDA nomination or a brief sponsor- submitted application.
White Paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program

Related Resources
All Resources

white-paper
Stability Study Design: Pharmaceutical Stability and Data Evaluation
Read More

post
Biologics vs Small Molecules: A New Era in Drug Development
Read More

case-study
Syner-G Partners with Leading Supplier in Life Sciences to Build Out New cGMP Compliant Facilities
Read More

case-study
Mobilizing Pharmaceutical Technology Transfers to a Contract Development and Manufacturing Organization (CDMO)
Read More
Let's move from science to success.
Let’s Talk